These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 26438354)

  • 61. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
    Abay M; Ozgen L; Yalcin Y; Ozerkan K
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
    Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
    DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
    AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A patient decision aid for risk-reducing surgery in premenopausal BRCA1/2 mutation carriers: Development process and pilot testing.
    Harmsen MG; Steenbeek MP; Hoogerbrugge N; van Doorn HC; Gaarenstroom KN; Vos MC; Massuger LFAG; de Hullu JA; Hermens RPMG
    Health Expect; 2018 Jun; 21(3):659-667. PubMed ID: 29281161
    [TBL] [Abstract][Full Text] [Related]  

  • 69. BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study.
    Loizzi V; Mongelli M; Arezzo F; Romagno I; Cazzato G; Popescu O; Legge F; Trerotoli P; Silvestris E; Kardhashi A; Cormio G
    Gynecol Obstet Invest; 2024; 89(2):87-94. PubMed ID: 38246147
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
    JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
    Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer.
    Meiser B; Price MA; Butow PN; Karatas J; Wilson J; Heiniger L; Baylock B; Charles M; McLachlan SA; Phillips KA
    Fam Cancer; 2013 Mar; 12(1):101-9. PubMed ID: 23203849
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    Cowan R; Nobre SP; Pradhan N; Yasukawa M; Zhou QC; Iasonos A; Soslow RA; Arnold AG; Trottier M; Catchings A; Roche KL; Gardner G; Robson M; Abu Rustum NR; Aghajanian C; Cadoo K
    Gynecol Oncol; 2021 May; 161(2):521-526. PubMed ID: 33712278
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy.
    Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL
    Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 79. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
    Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
    Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Beyond BRCA: Patterns of risk-reducing surgery for non-BRCA, homologous recombination repair pathway gene variant carriers.
    Lee SS; Karpel HC; Oh C; Smith J; Pothuri B
    Gynecol Oncol; 2023 Mar; 170():234-240. PubMed ID: 36724586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.